Fish oil pill flunks atrial fibrillation study

Omega-3 fatty acids have become a popular supplement taken by millions of people anxious to avoid heart disease. But the FDA says that a prescription strength version of the fish oil supplement failed to help patients with atrial fibrillation in a large study. A total of 663 patients suffering from erratic heart beats were split into two groups and given either the prescription treatment Lovaza or a placebo over a six month period. The drug was well tolerated but failed to register on the efficacy side of the equation. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.